Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Utah: - Farmington Health Center — Farmington, Utah
- University of Utah Sugarhouse Health Center — Salt Lake City, Utah
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- South Jordan Health Center — South Jordan, Utah
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.
Sponsor: University of Utah
NCT ID: NCT07166042
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Utah: - University of Utah Hospitals & Clinics — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Utah: - START Center for Cancer Care - Mountain Region — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Utah: - START Center for Cancer Research — West Valley City, Utah
Phase 2 Recruiting Academic/Other
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Sponsor: University of Utah
NCT ID: NCT06961955
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving …
Sponsor: University of Utah
NCT ID: NCT07203378
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Sponsor: University of Utah
NCT ID: NCT05464082
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to assess the feasibility of a wearing semiconductor embedded headband for cancer-related cognitive impairment in patients with breast or gynecological cancers. The study will also test the safety and effective…
Sponsor: University of Utah
NCT ID: NCT07173101
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06638307
Sites in Utah: - START Mountain — West Valley City, Utah
Phase 1 Recruiting Industry
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Utah: - Intermountain Health — Salt Lake City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Utah: - University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
- START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) an…
Sponsor: Eli Lilly and Company
NCT ID: NCT06400472
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
Sponsor: Radionetics Oncology
NCT ID: NCT07121244
Sites in Utah: - University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Sponsor: Radionetics Oncology
NCT ID: NCT06745804
Sites in Utah: - University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07361562
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future st…
Sponsor: ProteinQure Inc.
NCT ID: NCT07190469
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or mul…
Sponsor: University of Utah
NCT ID: NCT05291507
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah